Chemotherapy-induced peripheral neuropathy

Oncol Nurs Forum. 2005 Mar 5;32(2):305-11. doi: 10.1188/05.ONF.305-311.

Abstract

Purpose/objectives: To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy.

Data sources: Published abstracts, primary research literature, and textbook chapters.

Data synthesis: Recent improvements in the management of other treatment-related toxicities have led to peripheral neuropathy becoming a dose-limiting toxicity of commonly used chemotherapeutic groups such as platinols, vinca alkaloids, and taxanes.

Conclusions: The nervous system has not been the focus of education or training for oncology nurses. Therefore, nurses' ability to educate patients regarding this aspect of their condition has been limited.

Implications for nursing: With its significant impact on quality of life, peripheral neuropathy treatment and prevention are important components in the care of patients with cancer.

Publication types

  • Review

MeSH terms

  • Anticonvulsants / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Neoplasms / drug therapy
  • Patient Education as Topic
  • Peripheral Nervous System Diseases / chemically induced*
  • Peripheral Nervous System Diseases / nursing*
  • Peripheral Nervous System Diseases / physiopathology
  • Peripheral Nervous System Diseases / prevention & control
  • Quality of Life
  • Risk Factors

Substances

  • Anticonvulsants
  • Antidepressive Agents
  • Antineoplastic Agents